News
IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback